Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice

Figures

• 

  Fig 1. Schematic overview about the mouse genotypes and time points of protein level measurement.

• 

  Fig 2. SMN protein concentrations in blood. (A) Multiple comparisons of SMN concentrations in untreated or ASO-treated groups with and without PLS3 overexpression at P10 and P21 in comparison to WT and WT+ASO, respectively (see also Table 1). (B) Multiple comparisons of pooled groups at P10 and P21 showing SMN concentrations in comparison to WT and WT+ASO, respectively (see also S5 Table). (C) Longitudinal comparisons of pooled ASO-treated groups at P10 and P21 showed no significant differences in the SMN concentration between the two time points (see also S10 Table). (Dunn tests, multiple comparisons, Holm corrected). Only comparisons leading to a significant difference are shown (*P ≤0.05; **P ≤0.01, ***P ≤0.001).

• 

  Fig 3. Single group comparison for protein plasma concentrations of six putative biomarkers. Multiple comparisons of untreated and ASO-treated SMA and HET groups with and without PLS3 overexpression at P10 and P21 showing (A) COMP, (B) DPP4, (C) SPP1, (D) CLEC3B, (E) VTN and (F) AHSG concentrations in comparison to WT and WT+ASO, respectively (see also Table 1). (Dunn tests, Holm-corrected for multiple comparisons). Only comparisons leading to a significant difference are shown (*P ≤0.05; **P ≤0.01, ***P ≤0.001).

• 

  Fig 4. Protein plasma concentrations of six putative biomarkers in pooled groups. Multiple comparisons of unteated and ASO-treated pooled SMA and HET groups at P10 and P21 showing (A) COMP, (B) DPP4, (C) SPP1, (D) CLEC3B, (E) VTN and (F) AHSG concentrations in comparison to WT and WT+ASO, respectively (see also S5 and S6 Tables). (Dunn tests, Holm-corrected for multiple comparisons). Only comparisons leading to a significant difference are shown (*P ≤0.05; **P ≤0.01, ***P ≤0.001).

• 

  Fig 5. Correlations of SMN plasma protein with the concentration of biomarkers at P10. (A) COMP, (B) DPP4, (C) SPP1, (D) CLEC3B, (E) VTN and (F) AHSG. A linear model is fitted into the plots and the Spearman’s Correlation Coefficient ρ for each linear model is given in S8 Table.

• 

  Fig 6. Correlations of SMN plasma protein with the concentration biomarkers at P21. (A) COMP, (B) DPP4, (C) SPP1, (D) CLEC3B, (E) VTN and (F) AHSG. A linear model is fitted into the plots and the Spearman’s Correlation Coefficient ρ for each linear model is given in S8 Table.

• 

  Fig 7. Longitudinal comparisons of P10 with P21 of pooled protein plasma concentrations of six putative biomarkers. Pooled untreated and SMN-ASO treated groups at P10 were longitudinally compared with pooled P21-treated groups for each genotype. Diagrams show (A) COMP, (B) DPP4, (C) SPP1, (D) CLEC3B, (E) VTN and (F) AHSG (see also S10 Table). (Dunn tests, Holm-corrected for multiple comparisons). Only comparisons leading to a significant difference are shown (*P ≤0.05; **P ≤0.01, ***P ≤0.001).

• 

  Fig 8. Schematic overview of results for SMN and the six biomarkers.